Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

Marie Curie worked with radioactive material with her bare hands. More than 100 years later, Sophie Hardach travels to Paris ...

LANSING, Mich. and DELFT, Netherlands, June 20, 2025 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator and ...

Just over three years ago, Bayer was forced to concede that its blockbuster expectations for Xofigo (radium Ra 223 dichloride) would come to nothing, after the castration-resistant prostate cancer ...

Wiltshire Council knew about radioactive contamination at a former military base in January - but did nothing to alert the public.

Another big pharma company, Bayer, encountered difficulties when its radionuclide drug, Xofigo (radium Ra 223 dichloride), was found to cause more fractures and deaths in combination with Zytiga ...

Rates of anemia were slightly higher in the combination arm, at 22% compared to 16%. For drug discontinuation due to toxicity in [the olaparib plus Ra-223 arm], olaparib discontinuation was observed ...

Long-term results of the REASSURE trial (NCTO2141438) evaluating radium-223 (Ra-223, Xofigo) in patients with metastatic castration-resistant prostate cancer point to the agent’s strong safety profile ...

Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ...

The majority of men received ≥ 5 cycles of Ra-223. Early initiation of Ra-223 was associated with higher completion rates and better survival outcomes, underscoring the importance of early Ra-223 use ...